Bcr is a novel serine/threonine protein kinase that is believed to require two cysteine pairs for activity (Maru and Witte, Cell, 67, 459, 1991) . Tyrosine phosphorylated Bcr has dramatically reduced kinase activity, and tyrosine 360 of Bcr, which is one of the sites of phosphorylation by the Bcr ± Abl oncoprotein, is required for transkinase activity (Liu et al., Mol. Cell Biol., 16, 998, 1996) . Results presented here indicate that Bcr tyrosine 328 is also phosphorylated within Bcr ± Abl expressing cells and is required for Bcr's serine/threonine kinase activity. Bcr Y328F, like Bcr Y360F, had defective transkinase activity but can autophosphorylate. However, the Y328F/Y360F double mutant of Bcr is defective in both trans-and autokinase activities. Taken together with the kinase inhibitory eects of tyrosine phosphorylation of Bcr by Bcr ± Abl, our studies with tyrosine to phenylalanine Bcr mutants indicate that the hydroxyl residues of tyrosines 328 and 360 play crucial roles in Bcr's kinase activity.
Keywords: Bcr serine/threonine kinase; Bcr tyrosine residues; tyrosine phosphorylation of Bcr; inhibition of Bcr serine kinase by Bcr ± Abl; kinase role of Bcr tyrosines 328 and 360
Bcr is a novel protein kinase that phosphorylates target proteins on serine/threonine residues (Stam et al., 1987; Li et al., 1989; Maru and Witte, 1991) . The novelty is based on its unique structural characteristics. For example, Bcr does not possess the conserved amino acid residues found in the typical protein kinase (Li et al., 1989; Campbell and Arlinghaus, 1991; Maru and Witte, 1991) . However, Bcr contains a short amino acid sequence that resembles the ATP binding motif (Lifshitz et al., 1987) . The typical conserved motif involved in ATP binding contains a conserved stretch of glycines followed by a conserved valine at the carboxyl-terminal side of the consensus sequence (LG.G..G.V) (Hanks et al., 1988) ; the conserved valine is absent in the Bcr sequence (KG.G..G.D) (Campbell and Arlinghaus, 1991) . Moreover, although containing possible critical lysine residues within this ATP binding-like domain normally required for kinase function (Hanks et al., 1988) , mutation of these residues did not inhibit the kinase function (Maru and Witte, 1991) . Instead, mutation of the cysteine at residue 332 of Bcr inactivated the Bcr kinase. This cysteine is close to another cysteine (Cys 324) that may be part of a functional cysteine pair. A second pair of cysteines is present at residues 388 and 395. Similar cysteine pairs are thought to be involved in other novel kinases such as pyruvate kinase (Tomich et al., 1981) .
The Bcr gene was ®rst identi®ed because of its association with chronic myelogenous leukemia (CML). BCR and ABL genes undergo a rearrangement as the result of a reciprocal chromosomal translocation of chromosomes 9 and 22. The breakpoint in chromosome 9 is typically between the two alternate ®rst exons of ABL. The 3' ABL sequences become fused to the 5' portion of BCR on chromosome 22 where the breakpoint occurs usually within two small introns in the central part of the BCR gene (Shtivelman et al., 1986; Fainstein et al., 1987) . This abnormal chromosome 22 is termed the Philadelphia chromosome (Nowell and Hungerford, 1960) .
The Bcr protein is a target for the tyrosine kinase of the Bcr ± Abl protein Liu et al., 1993 Liu et al., , 1996 . Moreover, a small proportion of Bcr molecules forms a complex with Bcr ± Abl (Campbell et al., 1990) , probably by the way of heterotetramers (McWhirter et al., 1993) . The sites of phosphorylation on Bcr involve several tyrosines located within the ®rst exon . Our ®ndings indicate that the tyrosine 177 of Bcr, identical to that in Bcr ± Abl, is phosphorylated by Bcr ± Abl both in vitro (Puil et al., 1994) and in vivo (Ma et al., 1997) . We have identi®ed two other ®rst exon tyrosines that are phosphorylated by Bcr ± Abl (Liu et al., 1996) ; these are tyrosines 283 and 360. Surprisingly, we discovered that tyrosine phosphorylated Bcr lacked both auto-and transkinase activities (Liu et al., 1996) . Tyrosine 360 was found to be critical for Bcr's transkinase activity whereas tyrosines 283 and 177 were not. Therefore, we initiated studies to determine whether other tyrosines were involved in this kinase inhibition process induced by tyrosine phosphorylation. We report here that tyrosine 328 of Bcr in addition to tyrosine 360 is critically involved in the catalytic activity of Bcr. Mutation of both residues in Bcr severely inhibited Bcr's auto-and transkinase activities.
COS-1 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemental with 10% fetal calf serum. COS-1 cells were transiently transfected with various BCR cDNAs inserted into the pSG5 vector (Statagene, La Jolla, CA). Transfections were performed with the lipofectamine reagent (Gibco, Gaithersburg, MD) according to the manufacturer's protocol. BCR Tyr (Y) to Phe (F) mutants at residues 328 and 360 were generated using the Transformer sitedirected kit (Clonetech labs, Palo Alto, CA), as previously described (Liu et al., 1996) . Mutants were sequenced to con®rm the mutation and to ensure that no other mutations had been introduced. The BCR double mutant Y328F/Y360F DNA was generated by replacing the pstl-pstl fragment (containing Y360) of Bcr Y328F with the pstl-pstl fragment of BCR Y360F, which contains the 360 Y to F mutation.
COS-1 cells expressing various Bcr proteins were lysed 2 days after transfection. Immune complexes were obtained with anti-Bcr (1256 ± 1271). Protein kinase assays were performed as previously described . For transkinase measurements, Bcr immune complexes were added to the kinase reaction buer containing 10 mg of either casein or histone H1. Proteins were resolved by sodium dodecylsulfate/ polyacrylamide gel electrophoresis (SDS ± PAGE), and transferred to the Immobolin-P membrane (Millipore, Bedford, MA). Kinase activity was detected with a PhosphoImager (Molecular Dynamics, Sunnyvale, CA) or directly exposing to X-ray ®lm. Bcr protein levels were detected by ECL (Amersham, Arlington Heights, IL) with anti-Bcr (7C6, Santa Cruz, Santa Cruz, CA) using the same membrane.
In vivo orthophosphate labeling and 2D tryptic mapping procedures were described previously (Liu et al., 1996) . In brief, COS-1 cells cotransfected with BCR ± ABL and either wild-type or mutant BCR Y328F were labeled with [ 32 P]orthophosphate for 3 h. Cells were harvested and lysed under conditions that preserve phosphorylated tyrosine residues. Immunoprecipitated P160 BCR protein was resolved by SDS ± PAGE. Gel puri®ed Bcr was digested with trypsin and peptides separated on two-dimensional thin layer plates (Kodak, Rochester, NY) as described (Liu et al., 1996) .
Bcr tyrosine 328 is required for Bcr's transkinase activity
Of interest tyrosine 360, which is required for the transkinase function of Bcr (Liu et al., 1996) , lies between two pairs of cysteines (Figure 1 ). The cysteine pairs are located at residues 324/332 and 388/395. We noted that tyrosine 328 is located within this 5' cysteine pair. We, therefore, performed studies to determine whether tyrosine 328 like tyrosine 360 is also involved in Bcr's kinase catalytic activity. We mutated BCR tyrosine (Y) 328 to phenylalanine (F) and measured its serine/threonine kinase activity (Figure 2a) . Bcr (Y328F) mutant was expressed in COS-1 cells under conditions used previously (Liu et al., 1996) . Bcr protein was immunoprecipitated from COS-1 cell extracts with anti-Bcr (1256 ± 1271), and kinase assays performed. The results indicated that Bcr Y328F was defective in its ability to phosphorylate added substrates like casein (Figure 2a , lanes 2 and 6) and histone H1 (lanes 3 and 7) . The autokinase activity was somewhat reduced in the Y328F Bcr mutant (lanes 1 and 5). Thus, the Y328F Bcr mutant had a similar kinase phenotype as the Y360F Bcr mutant (Liu et al., 1996) . Western blotting established that Y328F Bcr was stably expressed in COS-1 cells, and the concentration of wild-type and mutant were similar in the above studies (Figure 2b) . Repeated experiments showed that Y328F Bcr (lane 4) had a faster mobility compared to either wild-type Bcr (lane 3) or Bcr mutants Y360F, Y177F, and Y283F (lanes 1, 2 and 5). Two possible interpretations could be considered that would change the mobility of Y328F Bcr. First, the reduction in the sites of autophosphorylation of Bcr in Y328F would increase its mobility in SDS gels (as suggested by experiments such as that shown in Figure  2a , lane 5 where the amount of kinase activity was reduced relative to wild-type Bcr, lane 1), or secondly, the conformation of Y328F Bcr is signi®cantly changed from wild-type Bcr so that its mobility increases in SDS gels. We favor the former explanation since the amount of autophosphorylation appears to be reduced in Y328F Bcr compared to wild-type Bcr or the other site-directed mutants tested (e.g. Y177F, Liu et al., 1996) .
Bcr Y328F/Y360F is defective in both auto-and transkinase activities
Since our studies show that tyrosine phosphorylated Bcr is defective in both auto-and transkinase activities (Liu et al., 1996) and since Bcr Y328F, like Bcr Y360F, is defective for transkinase activity, we made a double mutant in which both tyrosine 328 and 360 were changed to phenylalanine. The BCR double mutant Y328F/Y360F was expressed in COS-1 cells and kinase assays were performed (Figure 3a) . The results indicate that Bcr (Y328F/Y360F) was severely inhibited in its Figure 1 Bcr cysteine pairs and crucial tyrosines required for Bcr kinase activity. The involved cysteine (C) and tyrosine residues (Y) are enlarged and in boldtype. These residues are proposed to be required for Bcr serine, threonine kinase activity Two tyrosines required for Bcr's kinase activity Y Wu et al ability to both autophosphorylate and to transphosphorylate added substrates (Figure 3a, lanes 2 and 4) . Western blotting established that the double mutant was stable (Figure 3b ). In this experiment, the membrane used to monitor the auto-and trans kinase activity was also used to perform Western blotting with anti-Bcr (7C6, Santa Cruz Biotechnology, Santa Cruz, CA). The immunoprecipitates of the double mutant in this experiment contained signi®cantly higher amounts of mutant Bcr than the wild-type protein (Figure 3b , compare lanes 1 and 2 or lanes 3 and 4). Moreover, the double mutant had faster mobility, which was similar to that observed with Y328F Bcr (Figure 2b ). These ®ndings suggest the lack of autophosphorylation activity of the double mutant Y328F/Y360F Bcr also increased its gel mobility, but that the primary reason for the change in mobility was caused by the Y328F mutation. It is well known that phosphorylated proteins generally have slower mobility in SDS gels than non-phosphorylated proteins.
Bcr tyrosine 328 is phosphorylated by Bcr ± Abl in vivo
Our previous studies have identi®ed tyrosines 177, 283 and 360 of Bcr as sites of phosphorylation in vitro by Bcr ± Abl (Puil et al., 1994; Liu et al., 1996) . We also established that Bcr tyrosine 360 is also phosphorylated in vivo by Bcr ± Abl (Liu et al., 1996) . Moreover, our studies with Grb-2 binding indicate that tyrosine 177 of Bcr is also phosphorylated inside the cell (Ma et al., 1997) . Our strategy for identifying sites of tyrosine phosphorylation involves comparing 2-D phosphotryptic peptide maps of Tyr?Phe mutants to wild-type Bcr (or Bcr ± Abl). To determine whether tyrosine 328 is phosphorylated by Bcr ± Abl in vivo, we expressed either wild-type BCR or BCR (Y328F) in COS-1 cells along with BCR ± ABL, labeled the cells with [ Inspection of the BCR sequence indicates that the most likely tryptic peptide housing Y328 is a very long peptide beginning at Ser (S) 299 and extending through Arg (R) 352, termed S299/352R. That peptide would also contain Y316 as well as Y328. Its position in the map suggests a net four + charge and moderate hydrophobic character, which is consistent with its amino acid content. The presence of two oxidized cysteines as negative charges (two7), ®ve internal R/ Lys (K) residues (®ve +; and their sequence context would make them resistant to hydrolysis by trypsin), the amino terminal S (one +) and the carboxy terminal R (+) one would yield a total of seven positive charges in the oxidized peptide at the pH 2.1 buer condition. The three negative charges would include the two oxidized Cys residues and one phosphotyrosine residue (Y328). Thus, the most straight forward interpretation of the Y328F peptide mapping data is that Bcr Y328 is a site of phosphorylation by Bcr ± Abl. It is conceivable that Y316 (present within the S299/352R peptide) is also a site of phosphorylation within Bcr, but our studies argue against this since a doubly tyrosine phosphorylated peptide is unlikely, given the sequence being considered and its position in the 2D map (a four + net charge).
The role of tyrosines 328 and 360 in Bcr protein kinase activity
Our ®ndings indicate that tyrosines 328 and 360 are crucial for the catalytic mechanism used by the novel Bcr serine/threonine kinase. Mutation of either of these residues renders Bcr defective in its transkinase activities (Figure 2 of this paper and Liu et al., 1996) . Of importance, Tyr?Phe mutation of both tyrosines, blocked both auto-and transkinase activities (Figure 3 ). These two tyrosines are positioned in the vicinity of the two cysteine pairs believed to be required for Bcr kinase activity (Maru and Witte, 1991) (Figure 1 ). Tyrosine 328 is located between cysteines 324 and 332 (the ®rst cysteine pair), and tyrosine 360 is located between the two Cys pairs. What precise roles these two tyrosine play in the catalytic mechanism of the Bcr kinase is not known. Some hints as to the role of these tyrosines can be gained from the knowledge of the catalytic mechanism of pyruvate kinase (Annamalai and Colman, 1981; Tomich et al., 1981) . Their studies indicate that a critical tyrosine residue and two cysteine pairs play an important role in pyruvate kinase activity (Annamalai and Colman, 1981) . How these ®ndings apply to Bcr is unknown and therefore requires further studies. However, some useful information can be gained from comparing the eects of phosphorylation of tyrosines 328 and 360 and their mutation to phenylalanine residues. The outcome of mutating Bcr tyrosines 328 and 360 to phenylalanine is identical to that of tyrosine phosphorylation of Bcr with regards to inhibition of the Bcr kinase. Our ®ndings indicate that tyrosine phosphorylated Bcr lacks both auto-and transkinase activities (Liu et al., 1996) . Mutation of both of these residues to phenylalanine also blocks Bcr's auto-and transkinase activities (Figure 3 ). These ®ndings indicate that not only are tyrosine residues at these two positions in Bcr critical for Bcr kinase activity but the free hydroxyl residues are also critical. Replacing both hydroxyl groups with phosphodiester groups by phosphorylation of these tyrosines accomplishes the same inhibitory result as removing the hydroxyls by creating BCR (Y328F/Y360F). Phosphorylation of these two tyrosines may either adversely aect the structure of the Bcr kinase catalytic domain or by removing the hydrogen of the hydroxyl groups prevent the necessary interaction with other sequence elements of Bcr. That the hydroxyl group is important is strengthened by the eects of Y to F mutations. Surprisingly, the mutation of just one of these two tyrosine residues (either Y328 or Y360) blocks transkinase activity but not autophosphorylation to any great degree. Why the single mutation of tyrosine to phenylalanine would aect phosphorylation of added substrates like casein and histone H1 but not greatly aect autophosphorylation is not known. It should be noted that, as shown in Figure  2b , the mobility of Y328F Bcr in SDS gels is consistent with an alteration in the Bcr protein. This alteration must be subtle because the Y328F Bcr protein still retains some kinase activity as measured by autophosphorylation. Our ®ndings (shown in Figure 2a , lanes 1 and 5) suggest that the Y328F mutaton has more drastic eects on the autokinase of Bcr than the Y360F mutation (Liu et al., 1996) , and therefore support the hypothesis that the Y328F mutation is down regulating autophosphorylation of Bcr to some degree thereby altering Y328F Bcr mobility in SDS gels (Figure 2b ). The free hydroxyl groups of Y328 and Y360 seem likely to play a major role in the catalytic event. Based on the proposed crucial role of Bcr cysteine pairs reported by Maru and Witte (1991) , these tyrosines are likely to be involved in ATP transfer to the substrate. Our studies indicate that a synthetic peptide from the tyrosine 360 region did not inhibit the phosphorylation of added substrates like casein (results not shown). Thus, these results suggest that at least for tyrosine 360, interference with substrate binding may not be involved in the inhibitory eects.
No matter what mechanism is operational with tyrosines 328 and 360 in Bcr, our ®ndings indicate that their phosphorylation blocks Bcr's serine/threonine kinase function (Liu et al., 1996) . Other tyrosines like 177 and 283 do not seem to be involved in this catalytic mechanism because their mutation to phenylalanine does not aect Bcr's kinase activity (Liu et al., 1996) . Thus, we propose that the phosphorylation of tyrosine 328 and 360 within Bcr by Bcr ± Abl will drastically interfere with Bcr's kinase role in either signal transduction or some other cellular mechanism. What remains to be addressed is the physiological outcome of Bcr kinase inhibition by Bcr ± Abl in these leukemias. 
